Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
106. |
ECCT/15/11/05 | FALCI Study A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya 1. KEMRI Center for Respiratory Diseases Research (Siaya county) 2. KEMRI Walter Reed Kombewa (Kisumu county) 3. KEMRI Kisumu (Kisumu county) |
View |
107. |
ECCT/09/06/02 | A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples |
Principal Investigator(s) 1. Lisa Ann Mills Site(s) in Kenya Kisumu, Kenya |
View |
108. |
ECCT/23/10/01 | CROSSWALK Chronic (C) A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c) |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Doreen Terry Karimi Site(s) in Kenya 1. Gertrudes Childrens Hospital (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
109. |
ECCT/22/12/03 | heredERA A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
110. |
ECCT/22/11/03 | BFAST A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
View |